Status:
COMPLETED
Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab
Lead Sponsor:
Brigham and Women's Hospital
Collaborating Sponsors:
Genzyme, a Sanofi Company
Conditions:
Renal Transplantation
Eligibility:
All Genders
Brief Summary
The goal of the study is to find out the effects of two different drugs used at the beginning of organ transplantation on different populations of immune cells in the body of patients.
Eligibility Criteria
Inclusion
- all patients considered for transplantation
Exclusion
- none
Key Trial Info
Start Date :
September 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2011
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00842699
Start Date
September 1 2008
End Date
March 1 2011
Last Update
June 29 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115